List of bibliographic references
Number of relevant bibliographic references: 10.
List of associated KwdEn.i
Nombre de
documents | Descripteur |
|---|
| 5 | Antiviral |
| 3 | Adult |
| 3 | Aged |
| 3 | Female |
| 3 | Humans |
| 3 | Male |
| 3 | Medicine |
| 3 | Middle Aged |
| 3 | Viral hepatitis C |
| 2 | Administration, Oral |
| 2 | Antineoplastic agent |
| 2 | Drug Therapy, Combination |
| 2 | Gastroenterology |
| 2 | Genotype |
| 2 | Hepatitis B Surface Antigens (blood) |
| 2 | Hepatitis B, Chronic (diagnosis) |
| 2 | Human |
| 2 | Immunomodulator |
| 2 | Peginterferon alfa-2a |
| 2 | Treatment Outcome |
| 2 | Young Adult |
| 1 | Adolescent |
| 1 | Adverse event |
| 1 | Adverse events |
| 1 | Aged, 80 and over |
| 1 | Alanine Transaminase (blood) |
| 1 | Antiretroviral agent |
| 1 | Antiviral Agents (administration & dosage) |
| 1 | Antiviral Agents (therapeutic use) |
| 1 | Asia |
| 1 | Asunaprevir |
| 1 | Australia |
| 1 | Baseline |
| 1 | Baseline level |
| 1 | Biologic activity |
| 1 | Carrefio |
| 1 | Carrier State (diagnosis) |
| 1 | Chemotherapy |
| 1 | Chronic |
| 1 | Chronic hepatitis |
| 1 | Cirrhosis |
| 1 | Clin cancer |
| 1 | Consecutive weeks |
| 1 | DNA, Viral (blood) |
| 1 | Daclatasvir |
| 1 | Detection limit |
| 1 | Diagnostic Tests, Routine (methods) |
| 1 | Dos |
| 1 | Dose group |
| 1 | Dose levels |
| 1 | Dose-Response Relationship, Drug |
| 1 | Dosing |
| 1 | Drug Administration Schedule |
| 1 | Drug combination |
| 1 | Drug dose |
| 1 | Europe |
| 1 | Fibrosis |
| 1 | Follow-Up Studies |
| 1 | Fundacion jimenez diaz |
| 1 | Hbeag |
| 1 | Hepacivirus (classification) |
| 1 | Hepacivirus (genetics) |
| 1 | Hepacivirus (isolation & purification) |
| 1 | Hepatitis |
| 1 | Hepatitis B Surface Antigens (drug effects) |
| 1 | Hepatitis B surface antigen |
| 1 | Hepatitis B virus |
| 1 | Hepatitis B, Chronic (blood) |
| 1 | Hepatitis B, Chronic (drug therapy) |
| 1 | Hepatitis B, Chronic (mortality) |
| 1 | Hepatitis C virus |
| 1 | Hepatitis C, Chronic (drug therapy) |
| 1 | Hepatitis C, Chronic (virology) |
| 1 | Higher dose |
| 1 | Human interleukin |
| 1 | Imidazoles (administration & dosage) |
| 1 | Imidazoles (therapeutic use) |
| 1 | Immune system |
| 1 | Injection site |
| 1 | Injections, Subcutaneous |
| 1 | Interferon |
| 1 | Interferon alfa |
| 1 | Interferon-alpha (therapeutic use) |
| 1 | Internationality |
| 1 | Isoquinolines (administration & dosage) |
| 1 | Isoquinolines (therapeutic use) |
| 1 | Kaplan-Meier Estimate |
| 1 | Lamivudine |
| 1 | Liver center |
| 1 | Liver disease |
| 1 | Liver diseases |
| 1 | Local reaction |
| 1 | Longitudinal Studies |
| 1 | Lymphocyte |
| 1 | Markov Chains |
| 1 | Maximum increase |
| 1 | Miami school |
| 1 | Moderate decreases |
| 1 | Neutrophil counts |
| 1 | Normal range |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Allemagne/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i -k "Patrick Marcellin"
HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i \
-Sk "Patrick Marcellin" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Allemagne/Analysis/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Allemagne
|étape= Analysis
|type= indexItem
|index= Author.i
|clé= Patrick Marcellin
}}
| This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024 |  |
